Benefits
Cognitive performance + neuropsychiatric mood (Calapai 2017 PIVOTAL)
Calapai 2017 (PMID 29163162, Front Pharmacol 8:776) — 12-week double-blind placebo-controlled RCT in 111 healthy older adults. Cognigrape® 250 mg/day vs placebo. RESULTS: MMSE significantly improved (p<0.0001 vs baseline AND placebo). Beck Depression Inventory (BDI) reduced 15.8% vs baseline (p<0.0001) and vs placebo (p<0.0001). Hamilton Anxiety Rating Scale (HARS) reduced 24.9% (p<0.0001 vs baseline; p<0.05 vs placebo). RBANS total score improved (p<0.0001). Specific RBANS domains: ATTENTION (p<0.001), LANGUAGE (p<0.05), IMMEDIATE MEMORY (p<0.0001), DELAYED MEMORY (p<0.0001). Visuospatial unchanged. NO ADVERSE EFFECTS detected. Foundational pivotal RCT.
Short- and long-term cognitive performance (2024 follow-up RCT)
2024 follow-up RCT (PMC11431441, n=96 healthy older adults) confirmed Cognigrape® 250 mg/day improves SHORT-TERM (within 14 DAYS) and LONG-TERM (84-day) cognitive functions. Multiple domains: immediate and delayed memory, visuospatial abilities, language, attention. Continued improvement through 84 days. CONFIRMS Calapai 2017 findings with extended timeline characterization. Two-RCT evidence base supporting Cognigrape®.
Depression symptom reduction (15.8% BDI reduction)
Calapai 2017 demonstrated 15.8% Beck Depression Inventory reduction with Cognigrape® at 12 weeks (p<0.0001 vs baseline AND vs placebo). Notable for non-pharmaceutical food-grade extract producing measurable depression symptom reduction. Mechanism: combined cognitive enhancement + polyphenol mood effects + reduced systemic inflammation. Distinguishes Cognigrape® from pure cognitive enhancers.
Anxiety symptom reduction (24.9% HARS reduction)
Calapai 2017 demonstrated 24.9% Hamilton Anxiety Rating Scale reduction (p<0.0001 vs baseline; p<0.05 vs placebo). Comparable to dedicated anxiolytics in mild anxiety contexts. Mechanism: combined cognitive enhancement reducing anxiety from cognitive complaints + direct polyphenol effects on stress response. Important for older adults with anxiety-cognitive complaints.
Memory specifically (immediate + delayed) — robust signal
STRONGEST RBANS domain effects in Calapai 2017: IMMEDIATE MEMORY (p<0.0001) and DELAYED MEMORY (p<0.0001). Both at highest significance level (p<0.0001) vs placebo. Memory is the cognitive domain most concerning in age-related decline — Cognigrape®'s memory effects are clinically meaningful. 2024 follow-up confirmed across multiple memory measures.
Anthocyanin + proanthocyanidin polyphenol synergy
Distinguishing feature: high content of BOTH anthocyanins (dietary inflammatory/oxidative effects) AND proanthocyanidins (oligomeric/polymeric procyanidins for vascular and antioxidant effects). Sicilian grape variety selected for polyphenol profile. Mechanism: multi-target polyphenol matrix vs single-compound interventions.
Mechanism of action
Anthocyanin BBB penetration (CNS effects)
Anthocyanins from Cognigrape® cross BBB and exert direct CNS effects: neuroprotection, BDNF modulation, anti-inflammatory effects in microglia, antioxidant defense enhancement. Mechanism for cognitive enhancement and possibly mood effects.
Proanthocyanidin vascular effects
Proanthocyanidins improve endothelial function via NO production, reduce oxidative damage to vascular endothelium. Improved cerebral perfusion contributes to cognitive benefits. Mechanism complementary to direct CNS effects.
Resveratrol-related mechanisms
Sicilian grape extract contains resveratrol — SIRT1 activation, mitochondrial biogenesis support, neuroprotective effects. Mechanism for longevity-related cognitive benefits. Lower concentration than dedicated resveratrol supplements but contributes to overall polyphenol profile.
Antioxidant via direct ROS scavenging
Comprehensive polyphenol antioxidant profile — direct scavenging of hydroxyl, peroxyl, superoxide radicals. Particularly effective against oxidative damage in CNS where chronic inflammation contributes to age-related cognitive decline.
Anti-inflammatory NF-κB pathway modulation
Polyphenols suppress NF-κB activation and pro-inflammatory cytokine expression. Mechanism for chronic inflammation reduction. Relevant to systemic + neuroinflammatory cognitive aging.
BDNF and synaptic plasticity support
Polyphenol metabolites in CNS modulate BDNF expression and synaptic plasticity markers. Mechanism for cognitive enhancement, learning, memory. Distinct from acute receptor modulation.
Mood/depression effects via combined mechanisms
Combined cognitive enhancement (reducing cognitive-related anxiety/depression) + direct polyphenol effects on mood-related neurotransmitter systems + anti-inflammatory effects (depression has inflammatory component). Mechanism for documented BDI/HARS reductions in Calapai 2017.
Clinical trials
Randomized double-blind placebo-controlled clinical trial (Calapai G, Bonina F, Bonina A, Rizza L, Mannucci C, Arcoraci V et al. 2017, Front Pharmacol 8:776, doi:10.3389/fphar.2017.00776, PMID 29163162). PMC5671585.
111 healthy older adults randomly divided into two groups: Cognigrape® 250 mg/day (n≈55) vs placebo (n≈56) for 12 weeks. Cognitive function and neuropsychological status assessed via MMSE, Beck Depression Inventory (BDI), Hamilton Anxiety Rating Scale (HARS), and RBANS evaluations.
MMSE SIGNIFICANTLY IMPROVED vs baseline (p<0.0001) AND vs placebo (r=0.59, 95% CI 0.11-1.22, p<0.0001). BDI reduced 15.8% (p<0.0001 vs baseline AND placebo). HARS reduced 24.9% (p<0.0001 vs baseline; p<0.05 vs placebo). RBANS total score significantly improved (r=0.55, 95% CI 0.48-6.07, p<0.0001). RBANS domains: ATTENTION (p<0.001), LANGUAGE (p<0.05), IMMEDIATE MEMORY (p<0.0001), DELAYED MEMORY (p<0.0001). Visuospatial/constructional abilities NOT modified. NO ADVERSE EFFECTS detected. Foundational pivotal RCT.
Randomized double-blind placebo-controlled trial (PMC11431441, 2024).
96 healthy older adults randomized to Cognigrape® 250 mg/day vs placebo for 84 days. Multiple cognitive assessments at multiple time points.
SIGNIFICANT IMPROVEMENTS across multiple cognitive domains: IMMEDIATE memory, DELAYED memory, VISUOSPATIAL abilities, LANGUAGE, ATTENTION. Improvements occurring within 14 DAYS, continuing to improve after 84 days. CONFIRMS Calapai 2017 findings with extended timeline characterization. Demonstrates both short-term acute and long-term sustained benefits.
Comparative reference: Cocoa, Cognition, and Aging (CoCoA) Study (Mastroiacovo D, Kwik-Uribe C, Grassi D et al. 2015, Am J Clin Nutr 101:538-548, doi:10.3945/ajcn.114.092189).
Elderly subjects, cocoa flavanol consumption study — provides comparative context for grape polyphenol effects.
Confirmed cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects. Provides COMPARATIVE EVIDENCE for polyphenol-cognition mechanism establishing broader evidence base. Cognigrape® (grape polyphenols) operates through similar mechanism as cocoa flavanols — both established by RCT evidence.
About this ingredient
Cognigrape® is a STANDARDIZED SOLID EXTRACT from Sicilian grape (Vitis vinifera L.) developed by Italian biotechnology company BIONAP BIOACTIVE NATURAL PRODUCTS. Sicilian grape variety selected for high polyphenol content. STANDARDIZED FOR ANTHOCYANINS AND PROANTHOCYANIDINS — distinguishing feature is the multi-component polyphenol matrix vs single-compound standardization. Additional polyphenols include resveratrol, quercetin, and catechins. TRU-ID (DNA BARCODING) certified for authenticity. VEGAN OK certified. PIVOTAL CLINICAL EVIDENCE: CALAPAI 2017 PMID 29163162 (Front Pharmacol 8:776) — randomized double-blind placebo-controlled 12-week RCT in 111 healthy older adults at 250 mg/day. RESULTS: MMSE significantly improved (p<0.0001 vs baseline AND placebo), BDI reduced 15.8%, HARS reduced 24.9%, RBANS total score improved with strongest effects on IMMEDIATE MEMORY (p<0.0001), DELAYED MEMORY (p<0.0001), ATTENTION (p<0.001), LANGUAGE (p<0.05). Visuospatial/constructional abilities NOT modified. NO ADVERSE EFFECTS. CONFIRMATORY 2024 FOLLOW-UP RCT (PMC11431441, n=96): same 250 mg/day dose for 84 days, confirmed cognitive improvements within 14 days continuing through 84 days across multiple domains. TWO PUBLISHED RCTS support Cognigrape® cognitive + mood claims.
MECHANISMS: anthocyanin BBB penetration enabling direct CNS effects, proanthocyanidin vascular endothelial function effects via NO, resveratrol-related SIRT1/mitochondrial mechanisms, comprehensive antioxidant ROS scavenging, NF-κB anti-inflammatory pathway modulation, BDNF/synaptic plasticity support. UNIQUE PROFILE: COMBINED cognitive + mood (depression + anxiety) effects in single intervention. Few cognitive enhancers show measurable depression and anxiety effects; Cognigrape® demonstrated 15.8% BDI and 24.9% HARS reductions in pivotal RCT — clinically meaningful for older adults with combined cognitive-mood concerns. EVIDENCE: 2/5 reflects: (1) Calapai 2017 PMID 29163162 PIVOTAL 12-week RCT with multiple positive endpoints, (2) 2024 follow-up RCT confirming short + long-term effects, (3) industry-sponsored evidence (BioNAP) — important context but methodology rigorous, (4) Sicilian grape variety + standardization quality controls, (5) DNA barcoding authenticity certification, (6) NO adverse effects in 12-week trial, (7) UNIQUE combined cognitive + mood profile rarely seen in food-grade interventions. SAFETY: Excellent — food-grade grape origin with no adverse effects in clinical trials. Best positioned as: (a) COGNITIVE AGING with COMORBID MOOD/ANXIETY adjunct (where Cognigrape® has unique evidence), (b) MEMORY enhancement for older adults (immediate + delayed memory both p<0.0001 in Calapai 2017), (c) MILD DEPRESSION + ANXIETY in older adults preferring food-based interventions, (d) DAILY USE acceptable based on safety profile, (e) higher-evidence than typical 'grape extract' supplements due to standardization + RCT support, (f) industry-sponsored evidence — independent replication welcomed but methodology sound. Honest framing: Cognigrape® has more rigorous evidence than typical branded grape extracts — pivotal Calapai 2017 RCT with multiple positive endpoints (cognition, depression, anxiety) is methodologically robust. The combined cognitive + neuropsychiatric profile is genuinely unusual for food-grade extracts. 2024 follow-up confirmation strengthens evidence base. Industry sponsorship warrants caveat but is transparent. Reasonable cognitive aging + mild mood adjunct based on evidence.